Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.34 |
| ▸ | CDC42BPB | Q9Y5S2 | 3/20 | 0.34 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798635 | 0.74 | EGFR (0.39) | KDM4C | |
| SCHEMBL4163944 | 0.73 | JAK3 (0.40) | KDM4CJAK3JAK2JAK1 | |
| SCHEMBL7662481 | 0.71 | RIPK1 (0.46) | ROCK2ROCK1CDC42BPAKDM4ELRRK2 | |
| SCHEMBL3952312 | 0.70 | KDM4E (0.40) | KDM4E | |
| SCHEMBL4163921 | 0.68 | KDM4C (0.37) | KDM4C | |
| SCHEMBL7948683 | 0.68 | EGFR (0.33) | — | |
| SCHEMBL14250446 | 0.67 | MAPK8 (0.34) | — | |
| SCHEMBL312294 | 0.65 | EGFR (0.38) | LMNAKDM4E | |
| SCHEMBL4156178 | 0.65 | IRAK4 (0.32) | LMNA | |
| SCHEMBL13134200 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | KDM4C 2795/4885JAK3 4139/4885PDGFRB 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.